IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Humankind Investments LLC

Humankind Investments LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 30.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,190 shares of the medical research company’s stock after buying an additional 970 shares during the period. Humankind Investments LLC’s holdings in IQVIA were worth $823,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its stake in IQVIA by 0.8% in the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company’s stock worth $49,532,000 after purchasing an additional 1,750 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after acquiring an additional 56 shares during the last quarter. Czech National Bank raised its position in shares of IQVIA by 6.0% during the 4th quarter. Czech National Bank now owns 37,386 shares of the medical research company’s stock valued at $7,347,000 after acquiring an additional 2,107 shares in the last quarter. Finally, Claro Advisors LLC acquired a new position in IQVIA in the fourth quarter worth $281,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Down 2.9 %

IQV stock opened at $148.90 on Friday. The company’s 50 day simple moving average is $163.91 and its 200-day simple moving average is $188.25. The firm has a market capitalization of $25.76 billion, a P/E ratio of 19.85, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same period in the previous year, the firm earned $2.54 earnings per share. IQVIA’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

IQV has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Barclays reduced their price objective on IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, Hsbc Global Res downgraded IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $231.71.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.